B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1

Experimental and Molecular Medicine

Volumn 46, Issue 11, 2014, Pages

  Choi, Yong Won ^a   Kim, Hyun Ju ^a   Kim, Young Hwa ^a   Park, So Hyun ^a   Chwae, Yong Jun ^a   Lee, Jeonghun ^a   Soh, Euy Young ^a   Kim, Jang Hee ^a   Park, Tae Jun ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SODIUM IODIDE SYMPORTER; COTRANSPORTER; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1;

ARTICLE; B RAFV600E GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROMOTER REGION; PROTEIN EXPRESSION; THYROID CELL; THYROID PAPILLARY CARCINOMA; UPREGULATION; CARCINOMA; CELL CULTURE; CYTOLOGY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; POINT MUTATION; THYROID GLAND; THYROID TUMOR;

BASE SEQUENCE; CARCINOMA; CELLS, CULTURED; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; POINT MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; SYMPORTERS; THYROID GLAND; THYROID NEOPLASMS; UP-REGULATION;

EID: 84927731232     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.68     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184-199.
3. Yamashita H, Noguchi S, Yamashita H, Murakami N, Watanabe S, Uchino S et al. Changing trends and prognoses for patients with papillary thyroid cancer. Arch Surg 1998; 133: 1058-1065.
4. Ezaki H, Ebihara S, Fujimoto Y, Iida F, Ito K, Kuma K et al. Analysis of thyroid carcinoma based on material registered in Japan during 1977-1986 with special reference to predominance of papillary type. Cancer 1992; 70: 808-814.
5. Ros P, Rossi DL, Acebron A, Santisteban P. Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie 1999; 81: 389-396.
6. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994; 54: 4744-4749.
7. Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, Hoang-Vu C et al. Human thyrotropin receptor gene: Expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 1991; 82: R7-R12.
8. Ohta K, Endo T, Onaya T. The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues. Biochem Biophys Res Commun 1991; 174: 1148-1153.
9. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998; 83: 2493-2496.
10. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 2010; 17: 3294-3300.
11. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009; 16: 240-245.
12. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-6379.
13. Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) 2008; 68: 108-116.
14. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-262.
15. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840-2843.
16. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008; 15: 511-520.
17. Espadinha C, Santos JR, Sobrinho LG, Bugalho MJ. Expression of iodine metabolism genes in human thyroid tissues: Evidence for age and BRAFV600E mutation dependency. Clin Endocrinol (Oxf) 2009; 70: 629-635.
18. Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 2007; 13: 1341-1349.
19. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011; 121: 4700-4711.
20. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001; 20: 3139-3155.
21. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793.
22. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I et al. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006; 147: 5699-5707.
23. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M et al. The sodium/iodide symporter (NIS): Characterization, regulation, and medical significance. Endocr Rev 2003; 24: 48-77.
24. Kogai T, Brent GA. The sodium iodide symporter (NIS): Regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther 2012; 135: 355-370.
25. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr, Knauf JA et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: Functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 2006; 147: 1014-1019.
26. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 2006; 13: 257-269.
27. Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009; 69: 8317-8325.
28. Galrao AL, Sodre AK, Camargo RY, Friguglietti CU, Kulcsar MA, Lima EU et al. Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression. Endocrine 2013; 43: 225-229.
29. Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: Relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 1999; 84: 2449-2457.
30. Provenzano MJ, Fitzgerald MP, Krager K, Domann FE. Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg 2007; 137: 722-728.
31. Li W, Venkataraman GM, Ain KB. Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor. J Clin Endocrinol Metab 2007; 92: 1080-1087.
32. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-556.
33. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 2006; 27: 1160-1168.
34. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF, Minna JD. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 2004; 64: 3137-3143.
35. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111: 2364-2373.